2. Signaling Pathways
  3. Epigenetics
  4. YTHDF
  5. YTHDF2 Isoform

YTHDF2

YTHDF2 is a cytoplasmic m6A reader that controls m6A-modified RNA fate through mRNA degradation and, in selected contexts, translation regulation[1][2]. Mechanistically, YTHDF2-mediated mRNA decay targets multiple TGF-β signaling components in early postnatal mouse hippocampal neural stem cells, thereby limiting quiescence acquisition and supporting neurogenesis[1]. In glioma models, YTHDF2 accelerates UBXN1 mRNA degradation through METTL3-mediated m6A recognition, activates NF-κB signaling, and promotes malignant progression[3]. In glioblastoma stem cells, YTHDF2 instead stabilizes MYC and VEGFA transcripts, identifies a cancer-specific dependency, and links the YTHDF2-MYC-IGFBP3 axis to tumor growth[2]. Compared with related YTHDF isoforms, YTHDF proteins share m6A-reader activity but display distinct cellular functions because their low-complexity N termini, post-translational modifications, subcellular localization, and partner competition differ[4]. For experimental applications, linsitinib preferentially targeted YTHDF2-expressing glioblastoma stem cells, while a YTHDF2-specific small-molecule inhibitor suppressed tumor-cell translation and reversed paclitaxel resistance in ovarian cancer models[2][5].

YTHDF2 Related Products (9):

Cat. No. Product Name Effect Purity
  • HY-154919
    DC-Y13-27
    		Inhibitor 99.52%
    DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer.
  • HY-137341
    SK-3-91
    		Degrader 98.33%
    SK-3-91 is a PROTAC-type multi-kinase degrader that can jointly induce the degradation of the largest number of unique kinases (more than 125 unique kinases). SK-3-91 induces protein (YTHDF2, e.g.) degradation through the ubiquitin biotinylation (E-STUB) pathway. SK-3-91 degrades YTHDF2. SK-3-91 inhibits cell proliferation and induces morphological changes.
  • HY-173008
    YTHDF2-IN-1
    		Inhibitor 99.42%
    YTHDF2-IN-1 (Compound CK-75) is a selective YTHDF2 inhibitor (Kd = 26.2 μM). YTHDF2-IN-1 binds to a small hydrophobic pocket on the YTH domain of YTHDF2, disrupting the interaction between YTHDF2 and m6A-modified RNA. YTHDF2-IN-1 induces cell cycle arrest and Apoptosis. YTHDF2-IN-1 is applicable to research on chronic myeloid leukemia, colon cancer and choriocarcinoma.
  • HY-169396
    TAE648
    		Inhibitor 99.50%
    TAE648 is a target protein ligand of PROTAC SK-3-91 (HY-137341) (Ligand for Target Protein for PROTAC). TAE648 can be used for synthesis PROTAC. TAE648 decreases monolayer-cultured SKOV3ip1 cell viability.
  • HY-176848
    SKLB-Y13
    		Inhibitor 98.44%
    SKLB-Y13 is a selective YTHDF1 inhibitor with an IC50 of 0.76 μM and a KD of 5.097 μM. SKLB-Y13 binds to the Tyr397 and Trp470 residues in the m6A-binding pocket of YTHDF1, disrupting the interaction between YTHDF1 and m6A-modified mRNA. SKLB-Y13 inhibits cancer cell proliferation and promotes apoptosis. SKLB-Y13 is applicable to breast cancer-related research.
  • HY-168610
    YTH-IN-1
    		Inhibitor 98.66%
    YTH-IN-1 (compound N-7) is a pan-YTH domain inhibitor with the IC50 values of 39 μM, 34 μM, 35 μM, 48 μM and 30 μM for human YTHYTHDF1, YTHYTHDF2, YTHYTHDF3, YTHYTHDC1, and YTHYTHDC2, respectively.
  • HY-174982
    YTHDF2 ligand-1
    		Ligand 98.83%
    YTHDF2 ligand-1 (Compound 23) is a competitive, selective, and high-affinity YTHDF2 ligand with an IC50 of 11 μM and a Kd of 1.3 μM. YTHDF2 ligand-1 competes with m6A-RNA for binding to YTHDF2. YTHDF2 ligand-1 is applicable for cancer research.
  • HY-RS15938
    YTHDF2 Human Pre-designed siRNA Set A
    		Inhibitor

    YTHDF2 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-175885
    PROTAC FTO degrader 1
    		Inhibitor
    PROTAC FTO degrader 1 is a Fat Mass and Obesity-associated Protein (FTO) PROTAC degrader. PROTAC FTO degrader 1 selectively degrades FTO depending on VHL E3 ligase and ubiquitin-proteasome system. PROTAC FTO degrader 1 can increase m6A modifications on mRNAs associated with ribosome biogenesis and promote their YTHDF2-mediated decay. PROTAC FTO degrader 1 can inhibit cancer cells proliferation and induce apoptosis. PROTAC FTO degrader 1 can be used for the research of cancer, such as acute myeloid leukemia (AML). (Structure Note: Pink: FTO ligand (HY-175886); Blue: VHL ligand (HY-112078); Black: linker (HY-W002042); VHL ligand-Linker: (HY-139218))